ArticleFrontiers in cellular and infection microbiology2026
Varicella-zoster virus infection of the central nervous system: clinical features and proteomic analysis of cerebrospinal fluid.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Varicella-zoster virus (VZV) involvement of the central nervous system (CNS) can cause severe complications; however, the underlying pathogenic mechanisms remain incompletely understood. This study describes the clinical characteristics of VZV CNS infection and explores the molecular mechanisms involved through cerebrospinal fluid (CSF) proteomic analysis. Methods: This study included 69 patients diagnosed with VZV CNS infection at our center. Their clinical symptoms, laboratory tests, and neuroimaging results were analyzed. CSF samples from nine patients with VZV CNS infection (VZV group) and 10 controls without CNS infection (Ctrl group) were subjected to proteomic analysis. Results: The most common clinical manifestations were headache (79.7%), fever (56.5%), and motor/sensory disturbances (30.4%). Neuroimaging revealed abnormal brain parenchyma in 18.8% of the cases. CSF from most patients showed elevated white blood cell counts (0-1400 × 10 Conclusion: This study integrates clinical and proteomic analyses to reveal the clinical and molecular features of VZV CNS infection. Synergistic over-activation of the type I interferon response, inflammatory signaling, and lymphocyte activation drives a robust neuroinflammatory reaction, which may underlie blood-brain barrier disruption and neurological deficits. Furthermore, over-activation of the complement system in severe encephalitis provides new insights for understanding disease severity and potential therapeutic targets. These findings underscore the potential of this approach for developing diagnostic markers and targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.